Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

CERTIFIED SPINE AND PAIN CARE LLC

NPI: 1124561733 · WELLINGTON, FL 33414 · Interventional Pain Medicine Physician · NPI assigned 11/30/2016

$199K
Total Medicaid Paid
8,208
Total Claims
6,932
Beneficiaries
7
Codes Billed
2021-11
First Month
2023-03
Last Month

Provider Details

Authorized OfficialGARCIA, JORGE (CREDENTIALING DIRECTOR)
NPI Enumeration Date11/30/2016

Related Entities

Other providers sharing the same authorized official: GARCIA, JORGE

ProviderCityStateTotal Paid
BEAR LAKE COMMUNITY HEALTH CENTER, INC. GARDEN CITY UT $3.79M
JORGE O GARCIA, M.D., LLC NEWBERRY SC $518K
COMPLETE MEDICAL MANAGEMENT, LLC. MIAMI FL $123K
THE GREENLEAF CENTER A PSYCHOLOGICAL SERVICES CORPORATION WHITTIER CA $36K
BEAR LAKE COMMUNITY HEALTH CENTER, INC. GARDEN CITY UT $26K
CHRISTOPHER LEON DO PA MIAMI FL $157.00
DESCANSO HOME HEALTH SERVICES COVINA CA $0.00

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2021 57 $582.86
2022 6,930 $152K
2023 1,221 $46K

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
99214 Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity 4,535 3,819 $131K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 1,528 1,282 $47K
99204 Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity 315 272 $17K
62323 13 13 $2K
J1030 Injection, methylprednisolone acetate, 40 mg 184 183 $1K
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed 1,609 1,341 $0.00
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 24 22 $0.00